199 results about "Methicillin resistant Staphylococcus" patented technology

The invention provides a test strip for rapidly detecting methicillin-resistant staphylococcus aureus and application of the test strip, and belongs to the technical field of biochemical detection. The test strip comprises a bottom plate, a sample pad, a combination pad, a detection pad and a water absorption pad, the two ends of the detection pad are in lap joint with the combination pad and the water absorption pad respectively, the detection pad is located on the lower portion, the sample pad is in lap joint with the combination pad, and the combination pad is located on the lower portion; a detection line and a quality control line are arranged on the detection pad, the detection line is arranged on one side close to the combination pad, and the quality control line is arranged on one side close to the water absorption pad; the detection pad is coated with a MoS2 nanosheet, the combination pad is coated with a penicillin binding protein 2a polyclonal antibody labeled by horse radish peroxidase, and the detection line is coated with a penicillin binding protein 2a monoclonal antibody; the quality control line is coated with goat anti-rabbit IgG (immunoglobulin G). The kit is high in sensitivity and wide in linear range, has good specificity, repeatability and stability, and can effectively detect MRSA in a clinical sample.

The invention discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide has an amino acid sequence as shown in any one of SEQ ID NO: 1-11. The antibacterial peptide prepared by the scheme provided by the invention has very strong bacteriostasis and sterilization capabilities on methicillin-resistant staphylococcus aureus and multidrug-resistant escherichia coli, has application potential of becoming an antibacterial agent, a preservative or a disinfectant, and is not easy to generate drug resistance.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The invention provides a bridged triphenylamine-derived AIE type antibacterial photosensitizer, a preparation method and antibacterial application thereof, the bridged triphenylamine-derived AIE type antibacterial photosensitizer has the following structure: # imgabs0 is subjected to a cyclization reaction to form a bridged structure to limit bond rotation as a novel molecular design, and the photodynamic antibacterial effect of the AIE photosensitizer (PSs) can be effectively improved; and an AIE photosensitizer is combined with a donor-pi-receptor (D-pi-A) structure, so that a smaller singlet-triplet energy level difference (delta EST) is realized, and an intersystem crossing process is promoted. The mutual combination effect of the PSs and bacteria can be influenced by regulating and controlling the charge number of the PSs, so that effective bacteria recognition and selective antibacterial performance are realized. Experiments show that the AIE antibacterial photosensitizer based on bridged triphenylamine has a specific elimination effect on gram-positive bacteria; and the photodynamic antibacterial agent has a good photodynamic antibacterial effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus.

The invention provides a red light carbon quantum dot as well as a preparation method and application thereof. The red light carbon quantum dot is prepared from fulvic acid and polyamine as raw materials through a hydrothermal reaction. The fulvic acid is used as a carbon source, the polyamine is used as a nitrogen source, the carbon quantum dots are prepared through a hydrothermal reaction, the obtained carbon quantum dots are small in size, and the particle size is 1-3 nm; the red light emission wavelengths are 680 nm and 720 nm, and the photoluminescence characteristic is irrelevant to the excitation wavelength; the prepared quantum dot has good biocompatibility, the quantum efficiency is greater than or equal to 20%, the prepared quantum dot has good bacteriostatic and antibacterial activity, and the inhibition rate on staphylococcus aureus, pseudomonas aeruginosa, enterobacter cloacae, escherichia coli, klebsiella pneumoniae or methicillin-resistant staphylococcus aureus under the concentration of 2 mu g / mL can reach 99.9%. Wide application prospects are realized in the aspects of antisepsis, anti-inflammation and wound healing promotion.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The invention discloses a co-culture method of methicillin-resistant staphylococcus aureus and pseudomonas aeruginosa, and relates to the technical field of microbiology. Comprising the following steps: preparing materials: preparing methicillin-resistant staphylococcus aureus MRSA, pseudomonas aeruginosa PA and a culture medium; performing strain culture and activation, inoculating MRSA and PA, and performing subculture; preparing a bacterial suspension, and culturing MRSA and PA overnight; adding overnight culture bacterium liquid MRSA and PA into the culture medium, oscillating and uniformly mixing to prepare a bacterium suspension, and diluting for later use; the complete processes of strain preparation, bacterial suspension preparation, direct contact and indirect contact co-culture, drug sensitivity testing and the like are covered, and the interaction between MRSA and PA can be comprehensively researched; indirect contact co-culture is realized by adopting a Transwell insert, and a new method is provided for researching the interaction of two bacteria under the non-direct contact condition.

The invention discloses an antibacterial polypeptide AuGF and application of the antibacterial polypeptide AuGF in preparation of a medicine for treating and / or preventing bacterial infection. The amino acid sequence of the polypeptide is as follows: SEQ ID NO.1: GLFIKIIKIKIAKSF; the antibacterial polypeptide AuGF disclosed by the invention has broad-spectrum antibacterial activity, can effectively solve the problem of bacterial drug resistance, and has a remarkable bacteriostatic effect on various bacteria including staphylococcus aureus, streptococcus mutans, actinobacillus, methicillin-resistant staphylococcus aureus and the like; the compound provided by the invention has the advantages of simple preparation process and low cost, can play a significant role at low concentration, has low minimum inhibitory concentration on various pathogenic bacteria, has strong bacteriostatic ability, and is beneficial to reduction of side effects and improvement of drug safety; the antibacterial polypeptide AuGF can also be used as a bacteriostatic additive to be applied to articles of daily use, provides an effective bacteriostatic means for daily cleaning and skin care, and has a wide market application prospect.

Described herein are Staphylococcal toxins inspired peptides (STIPs) with antimicrobial activity, compositions and kits comprising the peptides, and use of the peptides to treat microbial infections. Also described are methods of inhibiting or preventing the growth of a microorganism, and methods of treating microbial infections such as bacterial infections including MRSA, and fungal infections including C. albicans.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

This invention discloses a method for preparing and applying a photothermal nanoreagent targeting bacteria. This invention utilizes Ti3C2T... x Using MXene as a matrix, a photothermal nanoreagent MXene@PDA@Peptide (MPP) was constructed by sequentially modifying the surface of Ti3C2Tx MXene with polydopamine and grafting it with the peptide CAEKA, which has the function of recognizing bacteria. Under the recognition of the peptide CAEKA, the photothermal Ti3C2Tx MXene was targeted. x MXene nanosheets are guided to the surface of bacterial cells, achieving effective sterilization at a relatively low overall temperature of around 50°C (or achieving more efficient sterilization at the same overall temperature level, exhibiting superior sterilization performance compared to pure Ti3C2Tx MXene). This makes them particularly suitable for the preparation of therapeutic drugs for subcutaneous abscesses caused by methicillin-resistant Staphylococcus aureus (MRSA) infection.

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.

The invention belongs to the technical field of natural antibacterial drugs, and discloses application of cyclovirobuxine D and pharmaceutically acceptable salts thereof in preparation of antibacterial drugs. The invention discloses the effect of cyclovirobuxine D in preparation of antibacterial drugs, and tests prove that cyclovirobuxine D has remarkable antibacterial activity in inhibition of gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli and super drug-resistant bacteria such as MRSA (Methicillin Resistant Staphylococcus Aureus).

The invention discloses a method for rapidly and efficiently preparing a series of novel ester group facaplysin derivatives by combining EDCI and HOBT to react with carboxyl facaplysin and directly carrying out ester exchange reaction on an active ester intermediate and alcohol without separation. The invention also discloses application of the derivatives in resisting methicillin-resistant staphylococcus aureus and escherichia coli. The preparation method comprises the following steps that EDCI and HOBT are combined to activate carboxyl facaplysin for reaction, an activated ester intermediate is generated, the activated ester intermediate and alcohol are directly subjected to esterification reaction without separation, and a series of ester-based facaplysin derivatives are obtained. According to the preparation method, ester-based Fascaplysin derivatives with different structures can be rapidly and efficiently constructed, and compared with a traditional method that ester-based carboline derivatives are firstly synthesized and then high-temperature intramolecular cyclization is performed, the time and the raw material cost are greatly saved, the synthesis efficiency is improved, the reaction process is observable and controllable, and the yield is stable. And the synthesized ester group facaplysin derivative has excellent antibacterial activity on methicillin-resistant staphylococcus aureus and escherichia coli.

The invention belongs to the technical field of organic synthesis, and relates to an electron donor-double receptor type fluorescent compound as well as a preparation method and application thereof, the electron donor-double receptor type fluorescent compound has the following structural formula: # imgabs0 #, R1 is at least one of the following functional groups: # imgabs1 # R2 is H,-CH3,-COOCH2CH3,-COOCH3 or-NO2; x1 is a halogen ion; the preparation method comprises the following steps: # imgabs2: mixing a compound as shown in a formula 2, a compound as shown in a formula 3 and organic alkali, and carrying out a Knoevenagel reaction to obtain the electron donor-double receptor type fluorescent compound. Compared with the prior art, the photosensitizer structure disclosed by the invention can efficiently generate active oxygen and shows an efficient photodynamic killing effect on methicillin-resistant staphylococcus aureus and escherichia coli. Due to the characteristics, the donor-double acceptor pyridinium salt derivative has important application value in the development of novel antibacterial materials.

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

The application belongs to the technical field of medical materials, and particularly relates to a sonodynamic Ag2O / MoS2 nanocomposite material as well as a preparation method and application thereof. The Ag2O / MoS2 nanocomposite material is prepared by depositing Ag2O on the surface of MoS2 to construct a heterostructure under the catalysis of a surfactant CTAB. The inhibition rate of the Ag2O / MoS2 nanocomposite material prepared by the application to 10 6 CFU / mL of Staphylococcus aureus, Escherichia coli and methicillin-resistant Staphylococcus aureus reaches 95.98% or more.

The invention discloses a photoresponsive antibacterial hydrogel, which comprises a photosensitizer, acrylamide, potassium 3-sulfopropyl methacrylate, chitosan quaternary ammonium salt, an additive and a cross-linking agent, and the structure of the photosensitizer (PD-Se) is shown in the specification. A photosensitizer (PD-Se) is added into hydrogel, the positive charge characteristic of QSA hydrogel remarkably improves the local enrichment concentration of PD-Se in thalli by enhancing the binding force with the bacterial surface, unsaturated fatty acid in a bacterial membrane lipid bimolecular layer is oxidized after photoinduced ROS is generated, guanine bases in a DNA double-helix structure are attacked at the same time, and therefore the bioactivity of the bacterial membrane lipid bimolecular layer is improved. The gel is endowed with photodynamic antibacterial ability, has an excellent sterilizing effect on escherichia coli, staphylococcus aureus and methicillin-resistant staphylococcus aureus, and can be used for preparing hydrogel dressing for wound repair.

The invention belongs to the technical field of medicines, and relates to application of an indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by staphylococcus aureus, in particular to application of the indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by drug-resistant staphylococcus aureus. The chemical structural formula of the indole-3-aryl ketone derivative disclosed by the invention is as shown in a formula I shown in the specification. Results of the invention show that the compound I (namely the indole-3-aryl ketone derivative as shown in the formula I) has strong inhibitory activity on methicillin-resistant staphylococcus aureus ATCC43300, the inhibitory effect is dependent on concentration gradient, the MIC50 value is 27.45 mu g / mL, and the MIC50 value of a positive drug streptomycin sulfate is greater than 200 mu g / mL. Therefore, the indole-3-aryl ketone derivative can be used for treating or preventing infectious diseases caused by the staphylococcus aureus.

Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a specific naphthoquinone compound, i.e. 2-hydroxy-1,4-naphthoquinone. One of these derivatives referred to as compound 6c in the series exhibits potent antimicrobial activity that is comparable to that of the two commercial antibiotics ofloxacin and ciprofloxacin against the two strains of methicillin sensitive Staphylococcus aureus (MSSA; ATCC 29213 and ATCC 6538). In the case of two strains of MRSA (ATCC BAA-44 and ATCC BAA-1717) that have developed drug resistance to both ofloxacin and ciprofloxacin, the antimicrobial activity of 6c can almost rival that of vancomycin and daptomycin. Furthermore, 6c is also effective against vancomycin-intermediate and daptomycin non-susceptible strain of MRSA (ATCC 700699). Besides the efficacy, 6c has a much improved drug resistance profile in comparison with the conventional antibiotics.

The invention provides an antibacterial active peptide YC18 and antibacterial application, and belongs to the technical field of biological medicine. The invention provides an antibacterial peptide. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The active polypeptide YC18 has different degrees of antibacterial activity to various bacteria, especially has MIC of 6.25 mu g / ml to staphylococcus aureus and methicillin-resistant staphylococcus aureus, and is good in antibacterial effect and high in sterilization speed. The active polypeptide YC18 has the capacity of inhibiting and removing a biofilm, is low in hemolytic activity and free of cytotoxicity, does not easily generate drug resistance in the use process, has an obvious protection effect on an abdominal cavity infection model, and has the potential of being applied as an anti-infection drug.

The invention relates to a mouse anti-PBP2a hybridoma cell line, a monoclonal antibody and an application thereof. The PBP2a protein of Staphylococcus aureus is extracted as an antigen. After obtaining a high-purity antigen, a good immune response is evoked in mice. Then, hybridoma technology is used to screen two cell lines with high affinity and specificity and prepare corresponding antibodies. The two antibodies are used as a gold-labeled antibody and a coating antibody in a colloidal gold immunoassay kit. The kit can be used to detect the PBP2a protein in methicillin-resistant Staphylococcus aureus and can be used for the development of related in vitro diagnostic reagents.

Composition for use for the treatment and / or prevention of infections or lesions of the (oral) mucosa, in particular originating from at least one selected the group consisting of: perleche; scarlet fever; pharyngitis; acute necrotising ulcerative mucositis; impetigo contagiosa; chelitis glandularis apostem atosa; gingivostomatitis herpetica; herpes simplex; herpes stabistis recidivans; herpes zoster; hand-foot-mouth; human papilloma virus; HIV; oral candidiasis; oral lichen planus; lichen ruber planus; leukoplakia, erythroplakia; methicillin-resistant staphylococcus aureus; gingivitis / periodontitis; mucositis / peri- implantitis; alveolar osteolytis; wherein the composition comprises or consists of the following components: (a) polyhexanide (PHMB); (b) an organic or inorganic buffer different from a); (c) further additives; (d) optionally water.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The invention discloses application of iso-pasteuretin in preparation of a medicine for treating diseases caused by methicillin-resistant staphylococcus aureus, and belongs to the technical field of biological medicine. According to the present invention, it is identified that the snowfield tea endophytic fungus 202109-Ts-F016 is the new Coprinopsis thamnolicola under coprinus pseudoratus, three monomeric compounds with anti-MRSA activity are separated from the secondary metabolite of the Coprinopsis thamnolicola, the three compounds can be adopted as the candidate inhibitors of the novel antibacterial target FtsZ, and the toxicity of the pasteurestin C and the iso-pasteurestin on the Vero cell is low. The invention provides an important basis and a material basis for the development of coprinus fungus metabolites and anti-MRSA new target drugs.

This invention belongs to the field of biomedical functional materials technology, and relates to an antibacterial and healing-promoting photosensitizer, its preparation method, and its uses. The photosensitizer is a defective MIL-88B@MIL-88C composite material, wherein defective MIL-88B serves as the substrate, and MIL-88C grows on the surface and / or in the pores of the defective MIL-88B. This photosensitizer significantly improves the photogenerated carrier separation efficiency, reduces impedance, enhances photocurrent response, and can efficiently generate reactive oxygen species under light irradiation. Antibacterial experiments show that it has excellent bactericidal effects against Staphylococcus aureus, Escherichia coli, and methicillin-resistant Staphylococcus aureus, and is not prone to inducing drug resistance. Simultaneously, this photosensitizer has good biocompatibility, promotes cell migration, and has significant hemostatic function. Animal models show that it can effectively accelerate the healing of skin defects.

Provided are compositions for controlling the growth of methicillin-resistant Staphylococcus aureus (MRSA). Uses of the compositions, alone or in combination with certain other agents, are also disclosed.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The invention discloses a method for rapidly detecting methicillin-resistant staphylococcus aureus and application of the method. According to the invention, a loop-mediated isothermal amplification (LAMP) technology is combined with a naturally extracted luminescent molecule-berberine for rapid detection of methicillin-resistant staphylococcus aureus. The operation process is simple and convenient, the dependence on instruments and equipment can be reduced, the detection cost can be greatly reduced by the luminous Chinese herbal medicine, the result judgment is performed by directly observing the generated fluorescence signal, the visualization and intuition of the detection result are realized, and the operation and result judgment of non-professional personnel are facilitated.